Study on Development of Assessment Guideline and Endpoints for Clinical Trial with Antitumor Natural Products

천연물 항암제제 임상시험 평가지표 개발연구

  • Published : 2006.12.25

Abstract

This study was perfromed to develop the assessment guideline and endpoints for clinical trial with anticancer herbal medicine. The botanical products used to humans for long time may be applied to phase 3 clinical trial after submitting the evidences for safety and efficacy of them or completion of basic requirement of phase 1 and phase 2 for safety confirmation and dose determination. Syndrome improvement was chiefly evaluated by Zubrod and karnofsky(%) methods. We suggest the general clinical trial assessment with botanical products, by following assessment points, that is, tumor size for 50 points, survival fate for 10 points, major syndromes for 40 points. It is recommendable that the each symptom of Qi deficiency syndrome, blood deficiency syndrome and Qi stagnation syndrome was allocated by assessment points, Similarly, the each symptom was given the assessment points according to the severity of symptom, for example, slight for 3 points, moderate for 2 points and severe for 1 point in hepatocelluar carcinoma and lung cancer. Then, the efficacy of botanical products was evaluated by the difference between pre-treatment and post-treatment. Asking the neoplastic patients of questionnaire on physical, emotional, cognitive, social and role subjects availability, three more syndromes (Fatigue, Pain and Nausea/Vomit), quality of life(QOL) will be evaluated by GLM statistics. In addition, in case of lung cancer, 13 questions will be asked by the EORTC QLQ-C13 forms. As the assessment of endpoints for efficacy to reduce side effects induced by chemotherapy and radiotherapy, the data of image scanning and hemato-urinalysis can be usefully applied on immune response, weight loss, indigestion, hemopoietic damage and injury of liver and kidney, while the changes of syndromes of side effect can be evaluated by differentiation methods of Qi and blood and five viscera. However, it is still necessary to determine the ratio between scientific analytical method and Oriental differentiation method as well as confirm the Oriental assessment endpoints by clinical trial. In addition, we suggest the continuous development of assessment endpoints on other carcinomas except of hepatocelluar carcinoma and lung cancer in future.

Keywords

References

  1. 식품의약품안전청, 천연물신약연구개발촉진법 제 2조, 법률제6165호 신규제정 2000
  2. 중화인민공화국위생부, 중약신약임상연구지도원칙, 제1집, 1993
  3. 중화인민공화국위생부, 중약신약임상연구지도원칙, 제2집, 1995
  4. 중화인민공화국위생부, 중약신약임상연구지도원칙, 제3집, 1997
  5. WHO/EDM/TRM, General guidelines for methodologies on research and evaluation of traditional medicine, 2000
  6. Center for Drug Evaluation and Research(CDER), Department of Health and Human Services Food and Drug Administration, Guidance for industry : botanical drug products, 2004
  7. EMEA, Guideline On The Clinical Assessment Of Fixed Combinations Of Herbal Substances / Herbal Preparations, Doc.Ref.EMEA/HMPC/166323, 2005
  8. 정수유. 중약신약임상연구 지도원칙 :시행(中藥新藥臨床硏究指導原則:試行), 중국의약기술출판사, 제024754호, 207-224, 2004
  9. 식품의약품안전청. 임상시험의 전반적인 고려사항, 생물의약품평가자료집 13, 2004
  10. National Cancer Institute(NCI), Cancer Clinical Trials: The Basic Workbook, National Institutes of Health(No.02-5050), 2001
  11. Center for Drug Evaluation and Research(CDER) & Center for Biologics Evaluation and Research(CBER), Guidance for industry : clinical trial endpoints for the approval of cancer drugs and biologics, 2005
  12. Food and Drug Administration, Guidance for industry: significant scientific agreement in the review of health claims for conventional foods and dietary supplements, USA, 1999
  13. WHO, QOL(quality of life) user manual : facet definitions and response scales, WHO, 601-671. 1998
  14. Bertil Axelsson, Tryck & Medier. The incurable cancer patient at the end of life, Uppsala University, 2001
  15. Martin, D. Abeloff, Clinical oncology, Churchill Livingstone Inc. 1999
  16. 대한의학협회 분과학회협의회 편저: 의학총서 암의 진단과 치료, 여문각, 23-35, 1992
  17. Anthony.J.Neal.ClinicalOncology3rdedition(basic principles and practice), Oxford University Press, 123-137, 2003
  18. 서울대 의과대학, 선경인더스트리 연구소: 제3세대 백금착제 항암제 신약개발 보고서, 보건복지부, 1994
  19. Katsutoshi Terasawa, Kampo, tokyo, K.K. Standard Mcintyre, 22, 1993
  20. Vencent T DeVita. Cancer principle and practice of oncology 4th ed., JB LIPPINCOTT Company, 678-887, 1993
  21. 왕영염주편, 중의내과학, 상무인서관, 391-397, 2000
  22. 양유걸주편, 암증종류의론의화정선, 약군문화사업공사, 408- 415, 1989
  23. EORTC, Study on Quality of Life Version 3.0, EORTC, 1995
  24. 浙江中醫學院學報編輯委員會, 腫留-中醫藥防治癌症病人放化療副反應, 浙江中醫學院學報, 6:49, 1986
  25. 鞠永棕編. 고오스 藥理學, 서울, 汎文社, 701-710, 1986
  26. 周雄順 外. 藥論惡性腫瘤 放化療後的中醫治療原則, 浙江中醫學院學報, 3:11-12, 1990
  27. 蔡德政. 黨蔘花粉治療放療化療所致造血功能障碍26例療效初步觀察, 中醫雜誌 11:25-26, 1987
  28. 徐悔文. 降逆湯防治腫瘤化療消化道反應三十七例, 浙江中醫雜誌, 1:5, 1989
  29. 金光 外. 中藥防治腫瘤化療毒副反應509例臨床觀察, 陜西中醫, 11:485, 1990
  30. 한국식품안전청 의약품안전국. 임상시험통계지침, 의약 65625-13553호, 2000
  31. Rosner. Fundamentals of Biostatistics, 5th Edition, 39, 2000
  32. Bishop, Fienberg & Holland. Discrete Multivariate Analysis, MIT Press, p 103, 1975
  33. Han, J.Y., Kim, H.K., Choi, B.G., Moon, H., Hong, Y.S., Lee, K.S. Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC). Jpn J Clin Oncol. 28(12):749-753. 1998 https://doi.org/10.1093/jjco/28.12.749
  34. 양검유등. 현대종류학, 상해의과대학, pp 425-428, 1993
  35. Wesley, M.N., Wesley, R.A. Biostatics in clincial trials In: Textbook of oncology., Williams and Wilkins, pp 346-348, 1986
  36. 이용구, 통계학원론, 율곡출판사, 199-222, 1991
  37. 이천림, 질변통계, 양유근 주편:위생통계학 제2판, 북경 인민위생출판사, 207-209, 1990
  38. Abrial, S.C., Penault-Llorca, F., Delva, R., Bougnoux, P., Leduc, B., Mouret-Reynier, M.A., Mery-Mignard, D., Bleuse, J.P., Dauplat, J., Cure, H., Chollet, P. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 3:1-9, 2005 https://doi.org/10.1007/BF01855120